CAR T 세포 치료 시장 : 브랜드별, 표적 항원별, 적응증별 - 세계 예측(-2030년)
CAR T-cell Therapy Market by Brand (Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2), Indication (Lymphoma, ALL, AML, Multiple Myeloma) - Global Forecast to 2030
상품코드:1518375
리서치사:Meticulous Market Research Pvt. Ltd.
발행일:On Demand Report
페이지 정보:영문 230 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 CAR T 세포 치료 시장은 2023년부터 2030년까지 43.3%의 CAGR로 2030년까지 516억 달러에 달할 것으로 예측됩니다.
이 보고서는 광범위한 2차 및 1차 조사와 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 도전 과제 및 기회 분석을 통해 작성되었습니다. 이러한 성장은 암 발병률 증가, CAR T 세포 치료에 대한 인식 증가, R&D 활동 및 임상시험의 증가에 기인합니다. 그러나 복잡한 제조 공정과 치료로 인한 부작용이 이 시장의 성장을 저해하고 있습니다.
또한, 신흥 경제권, 세포 치료의 기술 혁신, 제조 공정의 혁신은 이 시장에 진입하는 기업들에게 성장 기회를 제공할 것으로 예상됩니다. 그러나 CAR T 세포 치료의 높은 비용과 숙련된 전문가 부족은 시장 성장에 영향을 미치는 주요 과제입니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 시장 성장에 대한 영향요인
개요
성장 촉진요인
암 이환율 증가
CAR T 세포 치료에 대한 인식 확산
연구개발 활동과 임상시험 증가
성장 억제요인
복잡한 제조 공정
치료에 의한 부작용
기회
신흥 경제권의 전망
세포 치료와 제조 공정 혁신
과제
고액의 치료비
숙련된 전문가의 부족
규제 분석
가격 분석
파이프라인 제품 분석
환자 여정
상환 정책
Porter's Five Forces 분석
제5장 세계의 CAR T 세포 치료 시장·동향 분석 : 브랜드별
개요
Abecma (idecabtagene vicleucel)
Breyanzi (lisocabtagene maraleucel)
Kymriah (tisagenlecleucel)
Tecartus (brexucabtagene autoleucel)
Yescarta (axicabtagene ciloleucel)
Carvykti (ciltacabtagene autoleucel)
기타 브랜드
제6장 세계의 CAR T 세포 치료 시장·동향 분석 : 표적 항원별
개요
CD
BCMA
HER2
기타 표적 항원
제7장 세계의 CAR T 세포 치료 시장·동향 분석 : 적응증별
개요
림프종
급성 림프아구성 백혈병
다발성 골수종
급성 골수성 백혈병
기타 적응증
제8장 CAR T 세포 치료 시장·동향 분석 : 지역별
소개
북미
미국
캐나다
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽
아시아태평양
중국
일본
인도
기타 아시아태평양
라틴아메리카
중동 및 아프리카
제9장 경쟁 분석
개요
주요 성장 전략
벤더 시장 포지셔닝
경쟁 대시보드
업계 리더
시장 차별화 요인
선행 기업
신흥 기업
시장 점유율 분석/시장 순위(2022년)
제10장 기업 개요(사업 개요, 재무 현황, 제품 포트폴리오, 전략적 전개, SWOT 분석)
Novartis AG
bluebird bio, Inc.
Bristol-Myers Squibb Company
Caribou Biosciences, Inc.
Cartesian Therapeutics, Inc.
Pfizer Inc.
Cellectis S.A.
Celyad Oncology SA
Gilead Sciences, Inc.
Intellia Therapeutics, Inc.
Merck & Co., Inc.
Amgen Inc.
Inovio Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
기타 기업
제11장 부록
ksm
영문 목차
영문목차
CAR T-cell Therapy Market Size, Share, Forecast, & Trends Analysis by Brand (Abecma [idecabtagene vicleucel], Breyanzi, Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2) Indication (Lymphoma, ALL, AML)-Global Forecast to 2030.
The global CAR T-cell Therapy market is projected to reach $51.6 billion by 2030 at a CAGR of 43.3% from 2023 to 2030.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. This growth is due to increasing cancer prevalence, rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy restrain the growth of this market.
Furthermore, the scope in emerging economies, innovation in cell therapies, and manufacturing processes are expected to generate growth opportunities for the players operating in this market. However, high cost of CAR T-cell therapy, and lack of skilled professionals are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2023). The key players operating in the global CAR T-cell Therapy market are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).
Among all the drug types studied in this report, in 2023, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-cell therapy market. Yescarta (axicabtagene ciloleucel) has demonstrated superior effectiveness compared to other treatments. It exhibits high efficacy in treating high-grade B-cell lymphoma (HGBL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL) that have not responded to previous therapies, establishing its dominance in the CAR T-cell therapy market.
Among all the target antigens studied in this report, in 2023, CD target antigen segment is projected to register the highest CAGR during the forecast period due to strong product pipeline, the increasing clinical trials focusing on the CD antigen therapies, and the ongoing research studies to develop the therapies focusing on the CD target antigen.
Among all the indications studied in this report, in 2023, the lymphoma segment is expected to account for the largest share of the CAR T-Cell therapy market. Lymphoma is a group of blood cancers that develop from abnormal white blood cells or lymphocytes. Due to the increased cases of lymphoma, there was a rise in the adoption of CAR T-cell therapy for treating lymphoma, contributing to the large share of this segment.
An in-depth analysis of the geographical scenario of the global CAR T-cell therapy market provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the CAR T-cell Therapy market. In 2023, the U.S. is expected to account for the largest share of the CAR T-cell Therapy market in North America. The large share of this regional market is attributed to the presence of major CAR T-cell Therapy companies such as bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), and Caribou Biosciences, Inc. (U.S.), increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials in the region.
Scope of the Report:
CAR T-cell Therapy Market Assessment-by Drug Type
Abecma (idecabtagene vicleucel)
Breyanzi (lisocabtagene maraleucel)
Kymriah (tisagenlecleucel)
Tecartus (brexucabtagene autoleucel)
Yescarta (axicabtagene ciloleucel)
Carvykti (ciltacabtagene autoleucel)
Other Brands
CAR T-cell Therapy Market Assessment-by Target Antigen
CD
BCMA
HER2
Other Target Antigens
Note: Other target antigens include EGFR, GD2, MUC16, Lewis Y, and ROR1
CAR T-cell Therapy Market Assessment-by Indication
Lymphoma
Acute Lymphoblastic Leukemia
Multiple Myeloma
Acute Myeloid Leukemia
Other Indications
Note: Other indications include pancreatic cancer, breast cancer, ovarian cancer, scleroderma, HIV/AIDs, and autoimmune diseases.
CAR T-cell Therapy Market Assessment-by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Latin America
Middle East & Africa
TABLE OF CONTENTS
1. Overview
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Factors Affecting Market Growth
4.1. Overview
4.2. Drivers
4.2.1. Increasing Cancer Prevalence
4.2.2. Rise in Awareness Regarding CAR T-cell Therapy
4.2.3. Increasing R&D Activities and Clinical Trials
4.3. Restraints
4.3.1. Complex Manufacturing Process
4.3.2. Adverse Effects of the Therapy
4.4. Opportunities
4.4.1. Scope in Emerging Economies
4.4.2. Innovation in Cell Therapies and Manufacturing Processes
4.5. Challenges
4.5.1. High Cost of Therapy
4.5.2. Lack of Skilled Professionals
4.6. Regulatory Analysis
4.7. Pricing Analysis
4.8. Pipeline Product Analysis
4.9. Patient Journey
4.10. Reimbursement Policies
4.11. Porters Five Forces Analysis
5. Global CAR T-cell Therapy Market & Trend Analysis-by Brand
5.1. Overview
5.2. Abecma (idecabtagene vicleucel)
5.3. Breyanzi (lisocabtagene maraleucel)
5.4. Kymriah (tisagenlecleucel)
5.5. Tecartus (brexucabtagene autoleucel)
5.6. Yescarta (axicabtagene ciloleucel)
5.7. Carvykti (ciltacabtagene autoleucel)
5.8. Other Brands
6. Global CAR T-cell Therapy Market & Trend Analysis-by Target Antigen
6.1. Overview
6.2. CD
6.3. BCMA
6.4. HER2
6.5. Other Target Antigens
7. Global CAR T-cell Therapy Market & Trend Analysis-by Indication
7.1. Overview
7.2. Lymphoma
7.3. Acute Lymphoblastic Leukemia
7.4. Multiple Myeloma
7.5. Acute Myeloid Leukemia
7.6. Other Indications
8. CAR T-cell Therapy Market & Trend Analysis-by Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia-Pacific
8.5. Latin America
8.6. Middle East & Africa
9. Competitive Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Vendor Market Positioning
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis/Market Ranking (2022)
10. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
